Jakarta, March 30, 2026 – Based on the Consolidated Financial Statements of PT Enseval Putera Megatrading Tbk and its Subsidiaries (the "Company") as of December 31, 2025, and for the period then ended (Audited), the Company hereby informs that at the end of 2025, the Company's Net Sales were recorded at IDR 32,960.72 billion, representing a 6.47% increase compared to IDR 30,957.34 billion at the end of 2024.

The Company's Cost of Goods Sold at the end of 2025 was recorded at IDR 29,659.25 billion, an increase of 6.36% compared to IDR 27,885.42 billion at the end of 2024.

Thus, the Company recorded a Gross Profit of IDR 3,301.47 billion at the end of 2025, a 7.47% increase compared to the Gross Profit of IDR 3,071.92 billion at the end of 2024.

At the end of 2025, the Company's Operating Expenses were recorded at IDR 2,265.32 billion, consisting of Selling Expenses of IDR 2,011.03 billion and General and Administrative Expenses of IDR 254.29 billion, representing a 7.47% increase compared to the end of 2024. Therefore, the Company recorded an Operating Profit of IDR 1,036.15 billion, a 7.48% increase compared to the Operating Profit of IDR 964.05 billion at the end of 2024.

The Company's Profit Before Income Tax Expense at the end of 2025 was recorded at IDR 1,020.95 billion, an increase of 6.73% compared to the same period in 2024. Other Income (Expenses) consisted of finance income of IDR 12.20 billion, finance expenses of IDR 21.01 billion, final tax expense of IDR 3.75 billion, net profit share in associates of IDR 6.71 billion, other operating income of IDR 43.07 billion, and other operating expenses of IDR 52.42 billion.

The Company's Income Tax Expense at the end of 2025 was recorded at IDR 233.98 billion, an increase of 7.20% compared to the same period in 2024, which was IDR 218.26 billion.

As a result, the Company recorded a Profit for the Year of Rp786.97 billion at the end of 2025, a 6.59% increase compared to Rp738.33 billion for the same period in 2024.

Comparing the Company's Consolidated Statement of Financial Position as of December 31, 2025 (Audited) with the Company's Consolidated Statement of Financial Position as of December 31, 2024 (Audited), the Company's Total Assets increased by 14.32%, from Rp11.49 trillion to Rp13.13 trillion. The Company's Total Liabilities increased by 34.70%, from Rp3.91 trillion to Rp5.27 trillion. Consequently, the Company's Total Equity increased by 3.81%, from Rp7.58 trillion to Rp7.87 trillion.

Performance of Each Division
The Company currently has seven divisions, consisting of Consumer Goods, Prescription Drugs, Over-the-Counter Drugs, Raw Materials for Sale, Medical Equipment, Veterinary and Livestock Drugs, and Healthcare and Transportation Services.

The details of the performance of each division within the Company are as follows:

• The Consumer Goods Division contributed the largest share to total Net Sales, accounting for 37.33%. At the end of 2025, this division recorded Net Sales of IDR 12,304.44 billion.
• The Prescription Drugs Division contributed the second-largest share after the Consumer Goods Division, accounting for 35.44%. By the end of 2025, the Prescription Drugs Division recorded Net Sales of Rp11,682.79 billion, representing an 11.73% increase compared to the same period in 2024.
• The Over-the-Counter Drugs Division recorded Net Sales of Rp4,631.96 billion by the end of 2025, contributing 14.05% of the total revenue, an increase of 11.74% compared to the same period in 2024.
• The Raw Materials for Sale Division recorded Net Sales of Rp2,453.50 billion by the end of 2025, a 2.62% increase compared to the same period in 2024 and contributing 7.44%.
• The Medical Devices Division contributed 5.27% of the Company's revenue at the end of 2025, with Net Sales of Rp1,736.01 billion, a 5.81% increase compared to the same period in 2024.
• Net Sales from the Animal and Livestock Medicine Division were recorded at Rp55.80 billion, a 3.87% increase compared to the same period in 2024. The Animal and Livestock Medicine Division contributed 0.17% to the Company's total Net Sales.
• Net Sales from the Healthcare and Transportation Services Division were recorded at Rp96.22 billion, a 33.28% increase compared to the same period in 2024. This division contributed 0.29%.

About Enseval
Enseval is Indonesia's largest distribution company, having been operating since 1973 and employing over 4,400 people. Enseval went public on August 1, 1994, under the name PT Enseval Putera Megatrading Tbk (IDX: EPMT). In addition to distributing Kalbe Group products, Enseval is also trusted by other principals, both domestic and international. The Company has an extensive distribution network with three distribution centers located in Jakarta, Cikarang, and Surabaya, 48 branches across the Indonesian archipelago, and 24 branches through its subsidiary, PT Tri Sapta Jaya. To date, the Company has 10 subsidiaries operating in the distribution, raw materials, medical equipment, healthcare services, and transportation sectors.